Introduction
Psoriatic arthritis (PsA) is an increasingly common chronic systemic inflammatory disease that affects both the skin and the musculoskeletal system [1] [2] [3] . PsA can be characterized by pain and swelling of the joints, dactylitis, enthesitis, nail disease, and skin disease and increases the risk of cardiovascular disease and metabolic syndrome [4, 5] . The use of effective treatment improves patients' functionality and quality of life by reducing skin and joint involvement and preventing permanent joint damage [6] . Treatment options for PsA include nonsteroidal antiinflammatory drugs (NSAIDs), nonbiologic disease-modifying antirheumatic drugs (nbDMARDs), biologic agents (including tumor necrosis factor inhibitors [TNFis] ), and small molecules (including phosphodiesterase and Janus kinase inhibitors) [7] . From the rheumatoid arthritis (RA) literature, it has been demonstrated that use of these therapies is associated with a high rate of nonpersistence, attributed to dosing, route of administration, efficacy, and side effects.
Treatment persistence and prior biologic use are well documented in patients with RA and psoriasis; however, less is known about persistence in patients with PsA [8] [9] [10] [11] [12] [13] [14] . PsA is manifested in a diverse range of symptoms, and symptom severity varies over time, which complicates treatment and may influence treatment persistence [15, 16] . Factors associated with persistence differ based on prior biologic experience. The current study was undertaken to address this knowledge gap by describing persistence with TNFi in patients with PsA and to identify predictors of persistence, including the role of prior biologic use. This study provides a better understanding of the factors that influence discontinuation and switching of medications among patients with PsA with different biologic experience.
Materials and methods

Study design
The present study was a retrospective analysis of observational data collected on patients with PsA who participated in the Corrona registry and who initiated TNFi therapy.
Data source
Corrona is a large, US-based, independent, prospective, observational, disease-based registry with information on rheumatology patients, including those with PsA, since 2001. Patients are enrolled in the registry by participating rheumatologists, and questionnaires are completed by both patients and physicians as part of routine clinical care during clinical encounters. Data collection is not mandated at regular intervals; however, rheumatologists are encouraged to complete the questionnaires at least every 6 months. This registry encompasses over 160 sites across 40 states, including over 600 rheumatologists and 6000 patients with PsA (about 13% of the registry). This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Study population
Patients from the Corrona registry were included in this study if they had a physician-recorded diagnosis of PsA; initiated therapy (i.e., the index date) with a TNFi (i.e., adalimumab, etanercept, golimumab, or infliximab) between October 1, 2002, and March 21, 2013 ; and were at least 18 years of age at the index date. Included patients also had ≥1 follow-up visit captured in the registry after initiation of TNFi therapy. Patients were excluded from this study if they had a diagnosis other than PsA for which any of the qualifying TNFis might be used (e.g., ankylosing spondylitis, Crohn's disease, plaque psoriasis, RA, and ulcerative colitis).
Patients in this study were dichotomized as being persistent or nonpersistent. Patients were observed from the index date until the earliest instance of one of the following: last followup visit or nonpersistence (defined as discontinuation of TNFi therapy, switch to another biologic or small-molecule therapy, or a ≥1-year gap between follow-up visits).
Patients were further stratified by biologic experience. Biologic-naïve patients had no record of prior biologic use at TNFi initiation. Biologic-experienced patients had any record of prior biologic use at TNFi initiation.
Statistical analyses
Demographic and clinical characteristics were described at the index date. Kaplan-Meier curves were used to estimate median time to nonpersistence (i.e., discontinuation or switch to another biologic). Follow-up extended through the last visit for patients who were still on therapy at their last follow-up visit. Follow-up time was censored at the start of a gap in data if a patient had a gap ≥1 year between two visits before experiencing a discontinuation/switch event or last follow-up visit. A log-rank test was used to assess differences in persistence between patients who were biologic-naïve and biologicexperienced at the index date. Multivariate models were created to identify factors associated with TNFi nonpersistence with separate models for biologic-naïve and biologicexperienced patients. Univariate Cox proportional hazards models evaluated potential predictors: history of biologic use, patient demographics, history of comorbid conditions, and treatment history as of the index date; with the exception of gender, race, education, and treatment history as of the index date, all factors could vary over time. All factors that demonstrated a significant association with nonpersistence in the univariate models (p < 0.20) were then evaluated in multivariate Cox proportional hazards models, with the hazard ratios (HRs) from these two final models quantifying the effect of each factor as a predictor of nonpersistence for the biologic-naïve and biologic-experienced subpopulations.
Results
After applying the patient eligibility criteria, a total of 1241 TNFi initiations were identified for this study. These patients had a mean (standard deviation [SD]) age of 51 (12) years, 55% were female, 93% were white, and the study population had a mean (SD) PsA duration of 8 (9) years (Table 1) . At the index date, mean (SD) clinical disease activity index (CDAI) was 14.6 (12) , and the largest proportion of patients (44%) had CDAI ≤10 (i.e., low disease activity [LDA]; Table 2 ). The majority of patients had used a biologic (56%) or nonbiologic disease-modifying antirheumatic drug (nbDMARD) (86%) prior to initiating the index TNFi; 543 (44%) received monotherapy and 698 (56%) received combination therapy (Table 3) . Tables 1, 2 , and 3 also provide patient characteristics for biologic-naïve and biologic-experienced patients.
Time to TNFi nonpersistence
Overall, 46% of patients discontinued TNFi therapy during this study, with the number of persistent patients dropping from 83.2% at 6 months to 36.1% at 48 months. The follow-up time observed in this study was 1810.67 person-years. The median (95% confidence interval [CI]) time to discontinuation among all patients was 27 (25, 31) months. Among the 1241 TNFi initiations, there were 572 instances of nonpersistence, of which 309 instances were of switching.
Biologic-naïve patients were consistently more persistent than their biologic-experienced counterparts at all time points assessed over 4 years of follow-up ( Fig. 1) . At 6 months, 87% of biologic-naïve and 80% of biologicexperienced patients were persistent; at 48 months, 42 and 31%, respectively, were persistent. The median (95% CI) time to discontinuation among biologic-experienced and biologic-naïve patients was significantly different: 23 (18, 29) vs 32 (27, 37) months (p = 0.0002 from log-rank test; Fig. 2 ).
Predictors of TNFi nonpersistence
Multivariate Cox proportional hazard models were completed separately for biologic-naïve and biologic-experienced patients; models were adjusted for female gender, race, age, body mass index, smoking status, comorbidity, and concomitant prednisone use. In both biologic-naïve and biologicexperienced patients, activity based on the CDAI was associated with an increased risk of nonpersistence, although the magnitude of the association was greater in biologic-naïve patients: moderate CDAI (vs LDA) HR (95% CI) = 2.5 (1.5, 4.3) and 1.6 (1.1, 2.3) for biologic-naïve and biologic-experienced patients, respectively, and high CDAI (vs LDA) HR (95% CI) = 2.2 (1.1, 4.1) and 1.6 (1.0, 2.5) for biologic-naïve and biologic-experienced patients, respectively (Table 4) . Shorter disease duration was also associated with better persistence in both biologic-naïve and biologic-experienced patients. In patients who were biologic-experienced, the risk of discontinuation was higher among patients with prior nbDMARD treatment compared with patients with no prior nbDMARD treatment; the risk of discontinuation was also greater among patients with greater skin involvement (i.e., a high [>20] vs low [≤20] score on the physician global skin assessment).
Discussion
Based on results from a nationwide cohort of patients with PsA, slightly more than half (52%) of the patients included in this study were persistent with their TNFi therapy at 24 months Persistence is often associated with treatment efficacy [8] [9] [10] [11] [12] [13] [14] . The current study provides insight into the factors that influence persistence with a TNFi and how persistence differs based on prior exposure to biologics. Specifically, in patients who were biologic-naïve, disease duration and disease activity were associated with persistence. In addition to these factors, in patients who were biologic-experienced, prior medications and physician global skin assessment were also associated with persistence.
Most of the existing data on persistence and treatment outcomes describe patients with RA; there are fewer studies describing patients with PsA. Previous data indicate that patients with RA who fail their first biologic therapy experience worse efficacy on their second biologic [17] [18] [19] [20] . Patients who are biologic-naïve experience better efficacy when they start a new biologic compared with patients who are biologic-experienced. The association between biologic experience and persistence is fairly well established in RA populations [5, 21, 22] ; our study adds to the limited evidence suggesting that the pattern is similar in patients with PsA [23, 24] . Our overall rate of discontinuation was 46% including stopping, switching, or having a ≥1-year gap in treatment. In comparison, a study based on the DANBIO registry found that 39% of patients switched treatment and 17% of patients stopped treatment [24] . Of note, that study was focused on biologic-naïve patients only. Our findings are also consistent with another study that reported that, among patients who were biologic-naïve at TNFi initiation, there was no difference in persistence with TNFi between patients who initiated combination therapy (with methotrexate) and those who initiated monotherapy [25] .
Physicians who are treating biologic-naïve patients may be more willing to switch them to a new drug when their disease activity increases because they have more remaining therapeutic options available to try. Such a scenario would be consistent with our findings. Similarly, physicians may be less willing to quickly switch biologic-experienced patients when their disease activity increases because those patients have fewer remaining therapeutic options available to try [26] . Both of these scenarios suggest careful consideration in choosing the initial biologic to increase the likelihood of a favorable outcome with the first drug used. Even with such careful consideration, some patients may experience increases in disease activity and may need to switch to a different TNFi. The findings from this study overall suggest the need for careful and continued monitoring to ensure that patients remain persistent in order to enhance their opportunity to obtain the greatest therapeutic benefit from any TNFi that they may be using. Monitoring may also help physicians intervene and switch patients to a different medication when necessary.
An important strength of this study is its use of data from a national cohort of patients receiving care in both academic and private practice settings. As such, this study provides insights into TNFi persistence in the real-world, routine care setting.
Although one limitation associated with all real-world observational studies is that the patients enrolled in the registries may not be generalizable to patients in general practice, a recent study confirmed that Medicare patients represented in the Corrona registry are similar to the national Medicare population with regard to demographic characteristics, suggesting that data collected from patients in the Corrona registry may be generalizable to patients with RA in the USA [27] . As with most observational studies, there is the potential for selection bias in our study, especially given that the patients in our study entered the Corrona registry at the discretion of their treating rheumatologist. The PsA treatment landscape is evolving, with the availability of new agents possibly changing patterns of persistence. This issue was at least partially addressed by our decision to evaluate treatment-related covariates in a timevarying fashion for the models assessing predictors of persistence. Finally, we did not have access to data on reasons for TNFi discontinuation; consequently, the observed treatment nonpersistence could reflect either treatment success (i.e., achievement of LDA or remission) or failure (i.e., increased disease activity or worsening of symptoms).
Conclusion
The majority of patients with PsA assessed in this study were persistent with their TNFi therapy. When patients were stratified based on their previous biologic exposure, biologicnaïve patients had greater persistence compared with their biologic-experienced counterparts. While predictors of persistence differed slightly between biologic-naïve and biologicexperienced patients, disease activity was significant in both subgroups, although the magnitude of the association was a greater predictor for biologic-naïve compared with biologicexperienced patients. Understanding the factors associated with persistence in patients with PsA with different biologic experience may be important for making treatment decisions.
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